ACOR Fails To Walk The Talk, SNY Gets FDA Nod, New Use For Genmab's Old Drug

Acorda Therapeutics Inc. (ACOR) has decided to discontinue the development of Dalfampridine for treatment of post-stroke walking difficulties, following disappointing results from its trial, dubbed MILESTONE.

from RTT - Biotech http://ift.tt/2fXolnm
via IFTTT